Lung Transplantation for Pleuroparenchymal Fibroelastosis

Last updated: September 6, 2021
Sponsor: Hospices Civils de Lyon
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05044390
420
  • All Genders

Study Summary

This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Lung transplantation (any type) for pleuroparenchymal fibroelastosis
  • Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs

Exclusion

Exclusion Criteria:

  • All other interstitial lung disease than pleuroparenchymal fibroelastosis
  • Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation

Study Design

Total Participants: 30
Study Start date:
April 01, 2021
Estimated Completion Date:
November 01, 2021

Connect with a study center

  • Marie Lannelongue Hospital

    Le Plessis-Robinson, 92350
    France

    Active - Recruiting

  • Hopital Louis Pradel

    Lyon,
    France

    Completed

  • Bichat Claude Bernard Hospital, APHP

    Paris,
    France

    Active - Recruiting

  • Foch Hospital

    Suresnes,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.